Week of May 28, 2012: Astra Zeneca, GlaxoSmithKline Enter into Antibiotics Pact; Takeda to Acquire Multilab; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of May 28, 2012: Astra Zeneca, GlaxoSmithKline Enter into Antibiotics Pact; Takeda to Acquire Multilab; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca and GlaxoSmithKline have announced a EUR 224-million ($280 million) public–private partnership funding to enable development of antibiotics for bacterial infections and drive information sharing. The objective of the proposed research program is to improve the scientific understanding of antibiotic resistance, design and implement efficient clinical trials, and take novel drug candidates through clinical development. The program is part of the European Commission’s Action Plan Against the Rising Threats from Antimicrobial Resistance, launched in November 2011. Read More

Sixty-two percent of life-science executives are struggling to cope with and use effectively the amount of information flooding their inboxes, according to a new report from the communications consulting firm Mediaplanet. The company is publishing the report and potential solutions in The Independent’s June 29, 2012, issue and also will be discussing its findings at the 10th Annual Pharmaceutical IT Congress, to be held in London Sept. 17–18, 2012. The company aims through its report to address several issues for the pharmaceutical industry, including diversification, externalization of R&D processes, operational simplification, and smooth access to external innovation.

Takeda Pharmaceutical has agreed to acquire Multilab, a pharmaceutical company that specializes in generic drugs and OTC products. Takeda expects that the transaction will be finalized by the end of the second quarter of fiscal year 2012. Under the agreement, Takeda Brazil will acquire Multilab in cash for Brazilian Real (BRL) 500 million ($250 million) upfront and up to BRL 40 million ($20 million) in additional future milestone payments to the owners of Multilab. Read More

Industry Briefs:

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here